Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives-Reference-Cited by-同舟云学术

Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives

Published:2023-01 Issue: Volume:181 Page:103900
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Sirico Marianna,Virga Alessandra,Conte Benedetta,Urbini Milena,Ulivi Paola,Gianni Caterina,Merloni Filippo,Palleschi Michela,Gasperoni Marco,Curcio Annalisa,Saha Debjani,Buono Giuseppe,Muñoz Montserrat,De Giorgi Ugo,Schettini Francesco^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference92 articles.

1. Neoadjuvant endocrine therapy in breast cancer;Abrial;Breast (Edinb., Scotl.),2006

2. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer;Allevi;Br. J. Cancer,2013

3. Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor 2–negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial.

4. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy;Barker;Clin. Pharmacol. Ther.,2009

5. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer;Baselga;J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol.,2009

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Corrigendum to “Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives” [Crit. Rev. Oncol./Hematol. 181 (2023) 103900];Critical Reviews in Oncology/Hematology;2024-08

2. Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study;The Breast;2024-08

3. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer;ESMO Open;2024-07

4. Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature;The Breast;2024-06

5. Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials;Journal of Personalized Medicine;2024-04-27